

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Rockville, MD 20850, (Telephone Conference Call).

**Contact Person:** Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W260, Rockville, MD 20892-9750, 240-276-5856, [nadeem.khan@nih.gov](mailto:nadeem.khan@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 10, 2016.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-19416 Filed 8-15-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

**ADDRESSES:** Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.

#### FOR FURTHER INFORMATION CONTACT:

Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or

Email [ncitechtransfer@mail.nih.gov](mailto:ncitechtransfer@mail.nih.gov). A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** Technology description follows.

**Title of invention:** Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.

**Keywords:** Glypican-2, GPC2, Antibody, Immunotoxin, Recombinant Immunotoxin, RIT, Chimeric Antigen Receptor, CAR, Antibody-drug Conjugate, ADC, bispecific antibody, neuroblastoma.

**Description of Technology:** Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10–45%. This demonstrates a need for more effective therapies.

Glypican-2 (GPC2) is a cell surface protein that has been shown to be preferentially expressed on numerous pediatric cancers, including neuroblastoma. Due to this preferential expression, GPC2 represents a potential candidate for targeted therapy. Researchers at the National Cancer Institute's Laboratory of Molecular Biology (NCI LMB) have developed and isolated several single domain monoclonal human antibodies against GPC2. This technology covers the naked GPC2 antibodies as well as their use as targeting domains in recombinant immunotoxins (RITs) and chimeric antigen receptors (CARs). RITs (using clones LH1, LH4, or LH7) and CARs (using LH7) have shown specific killing activity against GPC2-expressing cells, suggesting that these candidates may be further developed as therapeutics.

The technology has been validated with *in-vitro* studies (human anti-GPC2 RITs and CARs can bind to, and kill, GPC2-positive tumor cells) and the researchers are currently developing mouse models to further develop GPC2-targeted therapies.

#### Potential Commercial Applications:

- Therapeutic applications include: Unconjugated antibodies, and use as targeting moieties for immunoconjugates such as CARs, ADCs, immunotoxins, and bispecific antibodies
- Diagnostic agent for detecting and monitoring target-expressing malignancies

#### Value Proposition:

- First to market potential—No current clinical trials with GPC2-targeted therapies
- Human antibody with high specificity and binding to targets results in less non-specific cell killing, therefore fewer potential side-effects for the patient
- Small size of single domain antibodies enhances stability, solubility, and target recognition
- Development Stage:** *In-vitro*.
- Inventor(s):** Mitchell Ho (NCI), *et al*.
- Intellectual Property:** US Provisional Application 62/369,861 (HHS Reference No. E-211-2016/0-US-01) filed August 2, 2016, entitled “Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.”

#### Collaboration Opportunity:

Researchers at the NCI seek parties interested in licensing or co-developing GPC2 antibodies and/or conjugates.

**Contact Information:** Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: [john.hewes@nih.gov](mailto:john.hewes@nih.gov).

Dated: August 8, 2016.

**John D. Hewes,**

*Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-19419 Filed 8-15-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Advisory Committee for Women's Services; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration's (SAMHSA) Advisory Committee for Women's Services (ACWS) on August 24, 2016.

The meeting will include discussions on child welfare and substance use disorders among families; improving the health of women and girls; recovery-oriented systems of care and what they mean for women; accountable health communities and how they relate to behavioral health; and a conversation with the SAMHSA Deputy of Operations and the Chief of Staff.

The meeting is open to the public and will be held at SAMHSA, 5600 Fishers Lane, Rockville, MD 20857, in Conference Room 5N76. Attendance by the public will be limited to space available. Interested persons may

present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person (below) on or before August 19, 2016. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact person on or before August 19, 2016. Five minutes will be allotted for each presentation.

The meeting may be accessed via telephone. To attend on site, obtain the call-in number and access code, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register on-line at <http://nac.samhsa.gov/Registration/meetingsRegistration.aspx>, or communicate with SAMHSA's Designated Federal Officer, Ms. Nadine Benton (see contact information below).

Substantive meeting information and a roster of Committee members may be obtained either by accessing the SAMHSA Committees' Web site <http://www.samhsa.gov/about-us/advisory-councils/advisory-committee-womens-services-acws> or by contacting Ms. Benton.

*Committee Name:* Substance Abuse and Mental Health Services Administration Advisory Committee for Women's Services (ACWS).

*Date/Time/Type:* Wednesday, August 24, 2016, from: 9:00 a.m. to 5:00 p.m. EDT, open.

*Place:* SAMHSA, 5600 Fishers Lane, Conference Room 5N76, Rockville, Maryland 20857.

*Contact:* Nadine Benton, Designated Federal Official, SAMHSA's Advisory Committee for Women's Services, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (240) 276-0127, Fax: (240) 276-2252, Email: [nadine.benton@samhsa.hhs.gov](mailto:nadine.benton@samhsa.hhs.gov).

#### Summer King,

*Statistician, Substance Abuse and Mental Health, Services Administration.*

[FR Doc. 2016-19422 Filed 8-15-16; 8:45 am]

BILLING CODE 4162-20-P

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG-2016-0437]

### Update to Alternative Planning Criteria (APC) National Guidelines

**AGENCY:** Coast Guard, DHS.

**ACTION:** Extension of comment period and notice of public meeting.

**SUMMARY:** Representatives from the U.S. Coast Guard's Office of Marine

Environmental Response Policy and Seventeenth District will meet on September 21, 2016, in Anchorage, Alaska. The meeting will be used as an opportunity to discuss Alternative Planning Criteria (APC) as they relate to oil spill preparedness pursuant to vessel response plan requirements. The meeting will be open to the public. In addition, the comment period for the notice published May 27, 2016, is extended.

**DATES:** The comment period for the notice published May 27, 2016 (81 FR 33685) is extended. Comments and related material must be submitted on or before Friday, September 23, 2016. The Coast Guard will meet Wednesday, September 21, 2016, from 8:30 a.m. to 3:00 p.m. Please note that the meeting may close early if all comments have been heard.

**ADDRESSES:** The meeting will be held in the Robert Atwood Room (Room 104) on the first floor of the Robert B. Atwood Building, 550 W. 7th Avenue, Anchorage, AK 99501. Parking will be available in the adjacent Lilly Pacillo Parking Garage. Parking tickets can be validated at the Atwood Building's Security Desk.

For information on facilities or services for individuals with disabilities, or to request special assistance at the meeting, contact the person listed in **FOR FURTHER INFORMATION CONTACT** below, as soon as possible.

To view the APC Guidelines, as well as public comments and any documents mentioned in this notice, go to <http://www.regulations.gov> and type "USCG-2016-0437," and click "Search." Then click "Open Docket Folder."

**FOR FURTHER INFORMATION CONTACT:** CDR Scott Stoermer, USCG Headquarters, 2703 Martin Luther King Jr. Ave SE., Stop 7516, Washington, DC 20593, [scott.a.stoermer@uscg.mil](mailto:scott.a.stoermer@uscg.mil), (202) 372-2234.

**SUPPLEMENTARY INFORMATION:** This public meeting is part of the public comment period already announced regarding the draft National APC Policy (81 FR 33685). To facilitate public participation, we are extending the comment period and holding a public meeting, and we invite public comment on the issues as listed in the "Agenda" section below. Comments previously submitted do not need to be submitted again.

#### Submitting Written Comments

If you submit a written comment, please include the docket number, indicate the specific material to which each comment applies, and provide a

reason for each suggestion or recommendation.

We encourage you to submit comments through the Federal eRulemaking Portal at <http://www.regulations.gov>. If your material cannot be submitted using <http://www.regulations.gov>, contact the person in the **FOR FURTHER INFORMATION CONTACT** section of this document for alternate instructions. Documents mentioned in this notice, and all public comments, are in our online docket at <http://www.regulations.gov> and can be viewed by following that Web site's instructions. Additionally, if you go to the online docket and sign up for email alerts, you will be notified when comments are posted or a final rule is published.

We accept anonymous comments. All comments received will be posted without change to <http://www.regulations.gov> and will include any personal information you have provided. For more about privacy and the docket, you may review a Privacy Act notice regarding the Federal Docket Management System in the March 24, 2005, issue of the **Federal Register** (70 FR 15086).

#### Public Meeting

A public comment period will be held during the meeting on September 21, 2016, from 12:00 p.m. to 3:00 p.m. Speakers are requested to limit their comments to 3 minutes. Please note that the public comment period may end before the time indicated, following the last call for comments. Contact the individual listed below to pre-register as a speaker. Pre-registration is not required to speak at the meeting as attendees will be able to note their desire to speak via the on-site meeting attendance/registration form. Written comments may also be brought to the meeting and will be included as part of the docket. Written comments submitted to the docket via <http://www.regulations.gov> do not need to be brought to the meeting.

The U.S. Coast Guard Office of Marine Environmental Response Policy is developing national-level policy to clarify APC submissions and processes pursuant to Title 33 Code of Federal Regulations, Part 155.1065 and 155.5067. While not a regulatory or rule-making activity, the Coast Guard is aware of the impact of the policy related to APC and its critical role in tank and non-tank vessel response preparedness. The goals of this public meeting are to: (1) Inform public entities of the status of Alternative Planning Criteria policy; (2) Inform public entities of the comments from earlier comment period(s); (3)